MELOXICAM; RIZATRIPTAN BENZOATE - Generic Drug Details

What are the generic drug sources for meloxicam; rizatriptan benzoate and what is the scope of freedom to operate?

Meloxicam; rizatriptan benzoate is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. There are seventy-nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Meloxicam; rizatriptan benzoate has two hundred and fifteen patent family members in thirty-two countries.

One supplier is listed for this compound.

Summary for MELOXICAM; RIZATRIPTAN BENZOATE

International Patents:	215
US Patents:	79
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MELOXICAM; RIZATRIPTAN BENZOATE
DailyMed Link:	MELOXICAM; RIZATRIPTAN BENZOATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MELOXICAM; RIZATRIPTAN BENZOATE

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MELOXICAM; RIZATRIPTAN BENZOATE

Drug Class	Nonsteroidal Anti-inflammatory Drug Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of Action	Cyclooxygenase Inhibitors Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for MELOXICAM; RIZATRIPTAN BENZOATE

M01AC	Oxicams
M01A	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01	ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M	Musculo-skeletal system

N02CC	Selective serotonin (5HT1) agonists
N02C	ANTIMIGRAINE PREPARATIONS
N02	ANALGESICS
N	Nervous system

Paragraph IV (Patent) Challenges for MELOXICAM; RIZATRIPTAN BENZOATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SYMBRAVO	Tablets	meloxicam; rizatriptan benzoate	20 mg/10 mg	215431	1	2025-06-30

US Patents and Regulatory Information for MELOXICAM; RIZATRIPTAN BENZOATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes

International Patents for MELOXICAM; RIZATRIPTAN BENZOATE

Country	Patent Number	Title	Estimated Expiration
Japan	2024102219	メロキシカムを含有する医薬組成物 (PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM)
Brazil	112020026965	uso de uma composição compreendendo meloxicam, rizatriptano e bicarbonato
Brazil	112020026965
Spain	3007857

Market Dynamics and Financial Trajectory for Meloxicam and Rizatriptan Benzoate

Last updated: February 20, 2026

What Are the Current Market Sizes and Growth Rates for Meloxicam and Rizatriptan Benzoate?

Meloxicam and Rizatriptan Benzoate target distinct segments within the pharmaceutical industry. Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), is primarily used for osteoarthritis and rheumatoid arthritis. Rizatriptan Benzoate, a triptan, is prescribed for acute migraine attacks.

Market Size and Growth

Drug	Estimated Global Market (2022)	Compound Annual Growth Rate (2023-2028)	Key Markets
Meloxicam	$1.2 billion	4.8%	US, Europe, Asia-Pacific
Rizatriptan Benzoate	$850 million	5.2%	US, Europe, emerging markets

Sources[1, 2] indicate that expansion driven by increased prevalence of chronic inflammatory conditions and migraines. The US accounts for approximately 50% of the meloxicam market and 60% of the rizatriptan market, driven by high healthcare expenditure.

What Factors Are Influencing Market Dynamics?

Meloxicam

• Patent Status: Many formulations are off patent, increasing generic competition. This has led to pricing pressure since 2018.
• Regulatory Approvals: Recent approvals for extended-release formulations expand usage, potentially increasing sales.
• Pricing and Reimbursement: US formulary listing favors low-cost generics, impacting revenue for brand-name versions.
• Competing Drugs: Diclofenac and naproxen maintain market share dominance, influencing demand patterns.

Rizatriptan Benzoate

• Pricing Strategies: High-cost branded versions face pressure from generics such as sumatriptan, affecting margins.
• Prescribing Trends: Increased adoption for early intervention in migraine episodes; however, some physicians prefer other triptans due to side-effect profiles.
• Market Entry: Emerging markets see increased availability through local generics, constraining prices but expanding volume.

How Will Market Drivers Affect Revenue Trajectories?

Meloxicam

Projected to reach $1.58 billion globally by 2028, driven by an aging population with arthritis, though profit margins shrink due to generic competition. Companies investing in bioavailability improvements or novel formulations can potentially offset volume pressure.

Rizatriptan Benzoate

Expected revenue reaching $1.1 billion by 2028, assuming a compounded growth rate of approximately 5%. The growth hinges on increased migraine prevalence and expanding access in emerging markets, counterbalanced by price erosion from generics.

What Are Investment and R&D Trends?

Meloxicam

• Research Focus: Development of topical formulations and combination drugs to differentiate products.
• Market Players: Major pharma companies like Boehringer Ingelheim and Teva investing in reformulations and new delivery systems.

Rizatriptan Benzoate

• Pipeline: Efforts to develop longer-acting formulations and combination therapies to improve adherence.
• Regulatory Activity: Some companies seek approval for intranasal or subcutaneous versions to diversify delivery.

How Do Market Risks Affect Future Outlooks?

• Patent Expirations: For meloxicam, looming patent expirations starting 2025 lead to increased generic competition.
• Regulatory Changes: Stricter opioid and NSAID prescribing policies can reduce market size.
• Market Access: Pricing reforms in Europe and Asia may pressure profits.
• Competition: Entry of biosimilars and newer agents may erode market share.

Summary of Financial Trajectories

Metric	Meloxicam	Rizatriptan Benzoate
2028 Revenue Forecast	$1.58 billion	$1.1 billion
CAGR (2023-2028)	4.8%	5.2%
Key Growth Drivers	Aging populations, formulation innovation	Migraine prevalence, market expansion

Key Takeaways

• Both drugs are mature markets with steady growth; the primary driver is increasing prevalence of their respective conditions.
• Patent expiry impacts revenue, especially for meloxicam.
• Market growth in emerging economies offers future upside.
• Competitive pressure from generics continuously erodes margins.
• R&D focuses on formulation enhancements and alternative delivery systems.

FAQs

1. How will generic competition influence future sales?
Generic entries will reduce prices and profit margins, especially after patent expiration, but volume sales may offset revenue declines.

2. Are there new formulations that could expand market share?
Yes. Extended-release meloxicam and intranasal rizatriptan aim to improve patient compliance and expand usage.

3. Which markets offer the greatest growth opportunities?
Emerging markets in Asia and Latin America, where access expands and registrations increase.

4. How do regulatory changes impact these drugs?
Tighter controls on NSAID use and migration to safer triptan alternatives impact prescribing patterns and market size.

5. What is the outlook for R&D investments?
Focused on improving delivery methods, safety profiles, and combination therapies to maintain competitive advantage amid price pressures.

---

References

[1] IQVIA. (2022). Global Pharmaceutical Market Report.
[2] MarketsandMarkets. (2023). NSAID and Triptan Markets by Region and Type.